EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
EULAR Evidence Based Recommendations for the Management of Hip Osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
OARSI Recommendations for the Management of Hip and Knee Osteoarthritis, Part I: Critical Appraisal of Existing Treatment Guidelines and Systematic Review of Current Research Evidence
OARSI Recommendations for the Management of Hip and Knee Osteoarthritis, Part II: OARSI Evidence-Based, Expert Consensus Guidelines
Glucosamine Sulfate in the Treatment of Knee Osteoarthritis Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study Using Acetaminophen as a Side Comparator
Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
Evaluation of the Effect of Glucosamine Administration on Biomarkers of Cartilage and Bone Metabolism in Bicycle Racers
Evaluation of the Effect of Glucosamine Administration on Biomarkers for Cartilage and Bone Metabolism in Soccer Players
Glucosamine Administration in Athletes: Effects on Recovery of Acute Knee Injury
Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis
Effects of Glucosamine, Chondroitin, or Placebo in Patients With Osteoarthritis of Hip or Knee: Network Meta-Analysis
Glucosamine and Chondroitin for Treatment of Osteoarthritis: A Systematic Quality Assessment and Meta-Analysis
Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers
Safety and Efficacy of Undenatured Type II Collagen in the Treatment of Osteoarthritis of the Knee: A Clinical Trial
Treatment of Rheumatoid Arthritis With Oral Type II Collagen. Results of a Multicenter, Double-Blind, Placebo-Controlled Trial
Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.
A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain
Calcium supplementation in osteoporosis
Prevention of Postmenopausal Osteoporosis — A Comparative Study of Exercise, Calcium Supplementation, and Hormone-Replacement Therapy
Calcium supplementation and bone loss in middle-aged women
Calcium Intake and Risk of Fracture: Systematic Review
Calcium Plus Vitamin D Supplementation and Risk of Fractures: An Updated Meta-Analysis From the National Osteoporosis Foundation
训练强度有多种解释，但在这里我们可以把训练强度理解为离力竭还差几个，通常用RIR（Reps In Reserve）表示。每组越接近力竭，那说明训练强度越高，RIR越低。假如你以前卧推用100kg，最多能做10个。那第10个就是RIR0（说明已经力竭了，一个不剩）。假如你刻意只做了9个，那就是RIR1（说明离力竭还剩1个）。假如你刻意只做了8个，那就是RIR2（说明离力竭还剩2个）。。。我已经在这篇文章里讲解过了，想要最佳的增肌效果，不应该把每组都练到力竭。相反，我们不应该做到力竭，应该在力竭之前还剩1-4个的时候停止。
3. Moya-camarena et al 1999. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha.
4. Moya-camarena et al 1999. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats.
5. Brown et al 2003. Isomer-specific regulation of metabolism and PPARgamma signaling by CLA in human preadipocytes.
6. Nazare et al 2007. Daily intake of conjugated linoleic acid-enriched yoghurts: effects on energy metabolism and adipose tissue gene expression in healthy subjects.
7. Hermann et al 2009. Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARgamma2 P12A polymorphism: a double blind, randomized, controlled cross-over study.
8. Brown et al 2001. Trans-10, cis-12, but not cis-9, trans-11, conjugated linoleic acid attenuates lipogenesis in primary cultures of stromal vascular cells from human adipose tissue.
9. Pinkoski et al 2006. The effects of conjugated linoleic acid supplementation during resistance training.
10. Watras et al 2007. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain.
11. Racine et al 2010. Effect of conjugated linoleic acid on body fat accretion in overweight or obese children.
12. Gaullier et al 2005. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans.
13. Gaullier et al 2004. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans.
14. Colakoglu et al 2006. Cumulative effects of conjugated linoleic acid and exercise on endurance development, body composition, serum leptin and insulin levels.
15. Sneddon et al 2008. Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin.
16. Blankson et al 2000. Conjugated linoleic acid reduces body fat mass in overweight and obese humans.
17. Chen et al 2012. Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population.
18. Norris et al 2009. Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus.
19. Laso et al 2007. Effects of milk supplementation with conjugated linoleic acid (isomers cis-9, trans-11 and trans-10, cis-12) on body composition and metabolic syndrome components.
20. Joseph et al 2011. Conjugated linoleic acid supplementation for 8 weeks does not affect body composition, lipid profile, or safety biomarkers in overweight, hyperlipidemic men.
21. Nazare et al 2007. Daily intake of conjugated linoleic acid-enriched yoghurts: effects on energy metabolism and adipose tissue gene expression in healthy subjects.
22. Larsen et al 2006. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain.
23. Lambert et al 2007. Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals.
24. Syvertsen et al 2007. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.
25. Venkatramanan et al 2010. Milk enriched with conjugated linoleic acid fails to alter blood lipids or body composition in moderately overweight, borderline hyperlipidemic individuals.
26. Diaz et al 2008. Chromium picolinate and conjugated linoleic acid do not synergistically influence diet- and exercise-induced changes in body composition and health indexes in overweight women.
27. Ribeiro et al 2016. Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-Blinded, and Placebo-Controlled Trial.
28. Wanders et al 2010. Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects.
29. Raff et al 2008. A diet rich in conjugated linoleic acid and butter increases lipid peroxidation but does not affect atherosclerotic, inflammatory, or diabetic risk markers in healthy young men.
30. Steck et al 2007. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans.
31. Malpuech-Brugère et al 2004. Effects of two conjugated linoleic Acid isomers on body fat mass in overweight humans.